INTRODUCTION
The high cost involved in the development of a new drug molecule has caused many pharmaceutical companies to divert greater attention to the development of new drug delivery systems. One of such delivery systems is gastroretentive drug delivery system (GDDS). Gastroretentive dosage formulations extend the duration of drug action by increasing time over which drug is released, thus increasing dosing intervals and patient compliance. Various gastroretentive techniques, including floating, swelling, high density, and bioadhesive systems, have been explored to increase gastroretention of dosage forms [1] .
Floating systems are low density systems that have sufficient buoyancy to float over the gastric contents and remain in the stomach without affecting gastric emptying rate for a prolonged period. While the system floats over the gastric contents, the drug is released slowly at the desired rate, which results in increased gastric retentive time and reduced fluctuation in plasma drug concentration [2] . The drug selected for this study, salbutamol sulphate, is a sympathomimetic amine used as a bronchodilator in the treatment of reversible bronchospasm. This drug is given in a daily dose of 4 -8 mg and has a short biological half-life (1.2 h).
A GDDS formulation of the drug may be advantageous over the conventional oral dosage form and inhaler due to its ability to maintain prolonged therapeutic concentrations in systemic circulation [3, 4] . Consequently, an attempt was made in the present work to develop a gastroretentive drug delivery system of salbutamol sulphate with a view to increasing the bioavailability of salbutamol sulphate.
EXPERIMENTAL Materials
Salbutamol sulphate, ethyl cellulose and Acrycoat S-100 (Corel Pharma Chem, Ahmedabad) were received as gifts from Cipla Laboratories, Himachal Pradesh, India. Sodium bicarbonate, citric acid (anhydrous) and tartaric acid were purchased from S.D. Fine-Chem Ltd, Ahmedabad, India. All other ingredients were of laboratory grade.
Preparation of floating tablets
All together, twenty four formulations, in four series (A to D), were prepared by wet granulation method.
Formulation A series
The composition of the formulations is mentioned in Table 1 . The tablet incorporated the drug (salbutamol sulphate), ethyl cellulose and Acrycoat S-100 as matrix formers, and sodium bicarbonate and citric acid as gas generating agents. All the powder ingredients (talc and magnesium stearate) were passed through a 177 µm aperture sieve separately. Salbutamol sulphate, the polymers and diluents were mixed thoroughly in a glass mortar and sufficient quantity of the binding agent added slowly to obtain a dough. The mass was sieved through a 2.0 mm mesh screen and dried on trays in a hot air circulation oven at 60 °C for 30 min. The dried granules retained on a 500 µm mesh were mixed with talc and magnesium stearate and then compressed into tablets using an automated single punch tabletting machine, keeping tablet hardness at 4 -5 kg/cm 2 and weight at 100 ± 5 mg.
Formulation B series
This formulations series (F8, F8.1 and F8.2) was prepared to improve the floating capability of the best formulation in A series, namely, F8, by incorporating an additional floating agent (tartaric acid) as well as its combination with citric acid. The method of preparation was the same as for A series; the composition of B series is shown in Table 2 .
Formulation C series
Formulations C series (FCT1 to FCT9) was made to increase the floating time of the tablets while decreasing the disintegration rate. A full 3 2 factorial design applied on the best formulation of B series by taking reduced proportion of tartaric acid and citric acid to obtain the formulations. Tablet preparation was the same as described above; the composition of the series is shown in Table 3 .
Formulation D series
Finally formulation design D (FCT8, FCT8.1 and FCT8.2) was optimized by incorporating mixtures of citric acid and tartaric acid in varying ratios while retaining the sodium bicarbonate content in F8 of formulation C series. The method of preparation was as described earlier for A series, and the composition is as shown in Table 5 .
Full factorial design

A 3
2 randomized full factorial design was used in this study. In this design 2 factors were evaluated, each at 3 levels, and experimental trials were performed at all 9 possible combinations.
In vitro buoyancy studies
In vitro buoyancy was determined by floating lag time and total floating time. The tablets were placed in a 100 ml beaker containing 0.1M HCl. The time required for the tablet to rise to the surface of the liquid and the duration of the time it remained floating were noted as floating lag time and floating time, respectively.
In vitro dissolution studies
In vitro dissolution studies on the tablets were carried out in a USP XXIII type 2 dissolution test apparatus, employing a paddle stirrer at 100 rpm in 900 ml of dissolution medium maintained at 37 ± 0.5 °C. The first 2 h of dissolution was carried out in hydrochloric acid buffer (HCAB, pH 1.2), followed by 5 h in phosphate buffer (PB, pH 6.8). At predetermined time intervals, 5 ml samples were withdrawn by means of a syringe fitted with a filter (0.22 µm, Raylab NZ, Ltd). The volume withdrawn at each interval was replaced with the same quantity of fresh dissolution medium. The samples were analyzed for drug release by measuring the absorbance at 225 nm spectrophotometrically (UV-1800, Shimadzu, Japan) after suitable dilution. All determinations were performed in triplicate [5] [6] [7] [8] .
Analysis of kinetics of drug release
To analyze the in vitro release data, various kinetic models, including zero order (Eq 1), first order (Eq 2) [9] , Higuchi (Eq 3) [10] , and Hixson-Crowell cube root law (Eq 4) [11] were applied to the data. 
Mechanism of drug release
Two relationships, Korsemeyer-Peppas and Weibull models [12, 13] , were applied to determine the mechanism of drug release as in Eqs 5 and 6, respectively. M t /M ∞ = kt n ……………..………… (5) where M t /M ∞ is the fraction of drug released at time t, K is the rate constant and n is the release exponent. The value of n was used to determine the drug release mechanism of the tablets.
log {-ln(1-M t /M ∞ )} = blogt + log t d ………… (6) where M t /M ∞ is the fraction of drug released at the log of time, t, and b was used to determine the drug release mechanisms of the tablets.
Statistical analysis
Statistical evaluation was performed by analysis of variance (ANOVA) using Microsoft Office Excel 2003 and confidence limit was set at 95 %. Regression coefficient (R 2 ) was used to determine how well a regression model describes the release data. Mean ± standard deviation (SD) for floating lag time and floating time were calculated using Microsoft Office Excel 2003.
RESULTS
Formulation A series
Bouyancy (floating time) data are shown in Table 1 . Floating lag time ranged from 60 to 80 s while duration of floating was 5 h for formulations F1 to F3 which contained only sodium bicarbonate as gas-forming agent. However, when sodium bicarbonate was combined with citric acid, the release of CO 2 increased, thus lowering floating lag time to a range varying from 30 to 70 s for formulations F4 to F9 (Table 1) . Formulation F8 exhibited the lowest lag time (30 ± 7 s) and longest floating duration (8±0.5 h*) compared. Consequently, F8 was used for optimization studies. showed the best fit to zero order with R 2 of 0.985 and 0.989, HCAB and PB, respectively, and also showed the highest level of drug release. Hence, F8 was considered the most suitable for optimization study. Table 2 shows the results of further optimization of F8. It reveals that formulation F8.2 exhibited longer duration of floating (9 h) and lower lag time (20 ± 3 s) than F8.1 (6 h and 30 ± 5 s, respectively). Therefore F8.2 
Formulation B series
FC = Formulation code, EC = ethyl cellulose, AS = Acrycoat S-100, SB = sodium bicarbonate, CA = citric acid, TA = tartaric acid, LA = lactose, TC = talc, MS = magnesium stearate, LT = lag time, DF = duration of floating
was selected for further optimization.
All formulations in the series followed more closely zero order kinetics with R 2 in the range of 0.981 to 0.991 and 0.972 to 0.981 in HCAB and PB media, respectively, compared with 0.951 to 0.962 and 0.940 to 0.954 in HCAB and PB, respectively, for the Higuchi model. F8.2 with R 2 of 0.991 and 0.981 in HCAB and PB, respectively, showed higher values than the other formulations in the series and, therefore, was selected for further optimization.
Formulation C series
As Table 3 shows, when citric acid and tartaric acid were incorporated in 1:1 ratio while increasing the proportion of sodium bicarbonate in the formulation in a full 3 2 factorial design, floating duration of the tablets increased from 6.0 ± 0.2 to 18.0 ± 0.5 h, while lag time decreased from 51 ± 7 to 22 ± 9 s; furthermore, the drug did not release rapidly from tablets not disintegrate rapidly. All tablets remained intact in HCAB. Formulation FCT8 was considered the best formulation on the basis of short lag time (22 ± 9 sec) and high duration of floating (18 ± 0.5 h).
When the release data for Formulations C series (FCT1 to FCT9) were subjected to five kinetic release models, the following R The n data obtained Korsmeyer-Peppas relationship suggested that all the formulations in the series exhibited nonFickian anamolous diffusion, except FCT5 and FCT6 which followed Case II transport and Super Case II transport, respectively (Table 4 ). Weibull data suggest that the formulations followed sigmoidal release which is indicative of a complex drug release mechanism where the rate of release increases up to the inflection point and thereafter declines. Hence, FCT8 was selected for further optimization. Table 5 indicates that Formulation series D exhibited lag time ranging from 22 ± 9 to 18 ± 10 s and duration of floating ranging from 18.0 ± 0.5 to 48.0 ± 0.5 h. FCT8.2 with good lag time of 18±10 s and duration of floating of 48 h was the best in the series.
Formulation D series
The Korsmeyer-Peppas n data suggest that FCT8 followed non-Fickian transport, i.e., anamolous transport while FCT8.1 and FCT8.2 followed Case II and super Case II transport, respectively. Weibull data suggest 
DISCUSSION
In formulation A series, sodium bicarbonate induced CO 2 generation in the presence of gastric fluid. The gas generated is trapped within the gel formed by hydration of the polymer, thus decreasing the density of the tablet. As the density of the tablet falls below that of gastric fluid, the tablet became buoyant.
The formulations containing a mixture of citric acid and sodium bicarbonate decreased lag time but increased floating duration, compared with formulations containing only sodium bicarbonate. This could be explained by the fact that sodium bicarbonate present in the formulation as an insoluble dispersion becomes soluble in the acidic medium provided by citric acid, and released Na + which reacted with the polymer and produced a cross-linked three-dimensional gel network [14] . Thus the trapped gas increases the duration of floating time.
Moreover, strong gellation of polymer slowed down the rate of water diffusion into the tablet matrix, which resulted in the retardation of drug release. Additionally, citric acid produced a stabilizing effect on the formulations by forming cross-linked gel network in the tablets. Hence, drug release rate was always slower for formulations containing citric acid than for those without it (F8).
Drug release from these gels was characterized by an initial phase of rapid release (burst effect). However, as gelation proceeds, the remaining drug was released at a slower rate and this feature indicates matrix diffusion kinetics.
In formulation B series, the effect of an additional floating agent (tartaric acid) on the duration of floating and floating lag time of formulation A (F8) was studied. The result was that the duration of floating increased.
When sodium bicarbonate reacts with citric acid and tartaric acid, it produces three and two molecules of CO 2 gas, respectively [15] . The combination of citric acid and tartaric acid accelerated the changes of pH value inside the tablet gel compared to the formulation without tartaric acid, because tartaric acid is more soluble than citric acid. This favors increased production rate of CO 2 and lowers the lag time of floating but enhances the duration of floating time. Thus the floating ability of the formulation is greatly dependent on appropriate mixture of citric acid and tartaric acid.
In formulation C series, increase in the concentration of sodium bicarbonate along with the incorporation of citric acid and tartaric acid in 1:1 ratio led to a decrease in drug release. This probably may be related to the solubility of the drug. Salbutamol sulphate has good solubility in aqueous solution at pH 7 but is sparingly to slightly soluble in alkaline solution. Sodium bicarbonate being alkaline in nature creates an alkaline microenvironment around the tablet and the drug is less soluble in alkaline pH which would decrease drug release from the tablet matrix. Formulation FCT8 was the best formulation on the basis of short lag time and high duration of floating.
Interestingly, for formulation D series, the incorporation of citric acid and tartaric acid in ratio 3:1 increased floating duration to as high as 48 h but it also decreased drug release from the tablet. The mechanism underlying the increase in floating duration is not known yet.
CONCLUSION
All the formulations exhibited good floating properties.
However, incorporation of appropriate ratio of citric acid and tartaric acid to enhance buoyancy under elevated stomach pH conditions caused retardation in drug release. Thus, by selecting a suitable composition of citric acid and tartaric acid (3:1) and sodium bicarbonate concentration 12 mg, as in i.e. FCT8.2, the highest floating duration and least lag time were achieved.
